Vital Therapies, Inc. (VTL) Releases Earnings Results, Beats Expectations By $0.06 EPS

Vital Therapies, Inc. (NASDAQ:VTL) issued its earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.06, Bloomberg Earnings reports. During the same quarter in the prior year, the firm earned ($0.30) earnings per share.

Shares of Vital Therapies (VTL) traded up 5.932% during mid-day trading on Friday, reaching $3.125. 158,386 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $2.89 and a 200 day moving average price of $3.71. Vital Therapies has a 52-week low of $2.25 and a 52-week high of $6.63. The firm’s market cap is $131.90 million.

ILLEGAL ACTIVITY WARNING: “Vital Therapies, Inc. (VTL) Releases Earnings Results, Beats Expectations By $0.06 EPS” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2017/08/04/vital-therapies-inc-vtl-releases-earnings-results-beats-expectations-by-0-06-eps.html.

In other Vital Therapies news, Director Muneer A. Satter acquired 20,000 shares of the business’s stock in a transaction dated Wednesday, June 14th. The stock was bought at an average price of $3.07 per share, with a total value of $61,400.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Muneer A. Satter acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, June 6th. The stock was acquired at an average cost of $3.19 per share, with a total value of $31,900.00. The disclosure for this purchase can be found here. In the last three months, insiders acquired 108,400 shares of company stock valued at $338,153. Corporate insiders own 29.88% of the company’s stock.

Several large investors have recently made changes to their positions in VTL. FMR LLC boosted its stake in shares of Vital Therapies by 102.9% in the first quarter. FMR LLC now owns 2,957,878 shares of the company’s stock worth $11,832,000 after buying an additional 1,500,000 shares during the period. Victory Capital Management Inc. boosted its stake in shares of Vital Therapies by 9.6% in the first quarter. Victory Capital Management Inc. now owns 2,549,439 shares of the company’s stock worth $10,197,000 after buying an additional 222,824 shares during the period. UBS Oconnor LLC acquired a new stake in shares of Vital Therapies during the first quarter worth about $800,000. LMR Partners LLP acquired a new stake in shares of Vital Therapies during the second quarter worth about $396,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Vital Therapies during the first quarter worth about $167,000. 26.62% of the stock is owned by institutional investors.

A number of research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Vital Therapies from a “sell” rating to a “hold” rating in a research report on Wednesday, May 10th. Raymond James Financial, Inc. started coverage on shares of Vital Therapies in a research report on Thursday, May 18th. They set an “outperform” rating and a $6.00 price target on the stock. Finally, ValuEngine lowered shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $8.00.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Earnings History for Vital Therapies (NASDAQ:VTL)

What are top analysts saying about Vital Therapies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vital Therapies Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit